WALTHAM, Mass.--(BUSINESS WIRE)--Naveris, Inc., the leader in precision oncology diagnostics for viral-related cancers, today announced that the Centers for Medicare & Medicaid Services (CMS) has ...

The MarketWatch News Department was not involved in the creation of this content. Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the ...

The NavDx test demonstrates high performance in detecting recurrent disease, providing an enhanced and widely accessible surveillance tool for HPV+ anal squamous cell carcinoma patients WALTHAM, Mass.

Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced that Palmetto GBA, the Medicare Administrative Contractor that administers the Molecular ...

WALTHAM, Mass., March 27, 2025--(BUSINESS WIRE)--Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the analytical validation of NavDx+Gyn, an ...

Rochester, Minn.-based Mayo Clinic is partnering with biotech company Naveris to launch a clinical trial of the company’s precision medicine blood test for tumor tissue DNA, NavDx. Naveris aims for ...

WALTHAM, Mass.--(BUSINESS WIRE)--Naveris, Inc., a leader in molecular diagnostics for viral cancers, today announced the launch of the DART 2.0 prospective clinical trial (NCT05541016) by Mayo Clinic.

Data presented showcases clinical utility of NavDx for patients with HPV-driven anal cancer Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, announced new data at ...

Recent Peer-Reviewed Data Reinforces Value of Molecular Residual Disease Testing in Head and Neck Cancer and Anal Cancer Surveillance Protocols Naveris, Inc., the leader in precision oncology ...

WALTHAM, Mass., September 27, 2024--(BUSINESS WIRE)--Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the presentation of new data at the 2024 ...